Short Talks Selected from Proffered Abstracts


PR-03 Addressing disparities in the Native American population in Oregon: The development of multidisciplinary frameworks to study pancreatic ductal adenocarcinoma in Native American communities. Jared Delaney. Brenden Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, United States.

PR-04 Therapeutic development platform for pancreatic cancer in the UK national health service: Lessons learned and initial results from Precision-Panc. David Chang. University of Glasgow, Glasgow, United Kingdom.

PR-05 CheMo4METPANC: Combination Chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naïve PANCreatic adenocarcinoma. Gulam Manji. Columbia University Irving Medical Center/New York Presbyterian, New York, NY, United States.

PR-06 CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study. Teresa Macarulla. Vall d'Hebrón University Hospital, Barcelona, Spain.

PR-07 Unravelling the epigenetic landscape of pancreatic cancer: The role of cancer-associated fibroblasts. Catarina Pelicano. CRUK University of Cambridge, Cambridge, United Kingdom.

PR-08 Spatial mapping of transcriptomic and lineage diversity in metastatic pancreatic cancer. Jimin Min. MD Anderson Cancer Center, Houston, TX, United States.

PR-09 Pancreatic cancer cachexia is mediated by tumor-derived PTHrP. Jason Pitarresi. University of Massachusetts Medical School, Worcester, MA, United States.


PR-11 KRAS mutant-specific interactions reveal mechanisms in pancreatic cancer tumorigenesis and metabolic function. G. Aaron Hobbs. Medical University of South Carolina, Charleston, SC, United States.
PR-12 **Targeting CDK7/9 in basal pancreatic cancer.** Sita Kugel. Fred Hutch Cancer Center, Seattle, WA, United States.

PR-13 **Single-cell mapping reveals a common origin for diverse subtypes of pancreatic cancer.** Nirakar Rajbhandari. University of California San Diego, La Jolla, CA, United States.

PR-14 **Ex vivo models of pancreatic cancer that recapitulate the metabolic tumor microenvironment identify glycine as a chemoresistance-inducing oncometabolite.** Alexander Muir. University of Chicago, Chicago, IL, United States.

PR-15 **Adenosine inhibits STING driven anti-tumor immunity in pancreatic cancer.** Alykhan Premji. UCLA, Los Angeles, CA, United States.

PR-16 **Neutrophil-intrinsic tumor necrosis factor (TNF) is a novel driver of T-cell and cancer-associated fibroblast (CAF) dysfunction in pancreatic cancer.** Anna Bianchi. University of Miami Miller School of Medicine, Miami, FL, United States.
Clinical Updates (Including Trials in Progress)

A001 Preoperative treatment with mFOLFIRINOX +/- isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): a randomised comparative multicenter phase II trial. Christelle Bouchart. Institut Jules Bordet - HUB, Brussels, Belgium.

A002 A Phase II Study of Peri-operative Modified FOLFIRINOX in Localized Pancreatic Ductal Adenocarcinoma (PDAC). Michael Cecchini. Yale University School of Medicine, NEW HAVEN, CT, United States.

A003 Preliminary Safety Results from a Phase I Study of Autologous Transgenic T Cells Expressing High Affinity Mesothelin-Specific T Cell Receptor (TCR) (FH-TCR TMSLN) in Patients (Pts) with Metastatic Pancreatic Ductal Adenocarcinoma (mPDA). Elena Chiorean. University of Washington, Seattle, WA, United States.

A004 Lymphopenia and spleen dose for inoperable pancreatic cancer patients receiving ablative 5-fraction radiation therapy. Michael Chuong. Miami Cancer Institute, Miamia, FL, United States.


Diversity and Disparities


A007 Expression and activity of Rac, Cdc42, and their downstream effector PAK in Puerto Rican pancreatic cancer patients. Anamaris Torres-Sanchez. University of Puerto Rico at Rio Piedras Campus, San Juan, Puerto Rico.


Epidemiology and Early Detection

A009 Association between unstable diabetes mellitus and risk of pancreatic cancer. Sitwat Ali. QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
A010 **Evaluation of the Avantect Pancreatic Cancer Test for Identifying High-Risk Pancreatic Cysts.** Anna Bergamaschi. ClearNote Health, San Diego, CA, United States.


A012 **The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): Genetic testing and follow-up of high risk individuals.** Julie Earl. Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain.


A014 **Combinations of previously reported biomarkers achieve improved sensitivity and specificity of detection of early stage pancreatic ductal adenocarcinoma.** Brian Haab. Van Andel Institute, Grand Rapids, MI, United States.

A015 **Impact of healthy lifestyles and polygenic risk scores on pancreatic cancer risk: the Multiethnic Cohort Study.** Veronica Wendy Setiawan. Keck School of Medicine of USC, Los Angeles, CA, United States.

A016 **Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18F-labeled rBC2LCN lectin.** Yukihito Kuroda. University of Tsukuba, Tsukuba, Japan.

A017 **Lipidomic biomarkers of usual alcohol use and their association with pancreatic ductal adenocarcinoma risk.** Sabine Naudin. International Agency for Research on Cancer, Lyon, France.

**Immunology and the Microenvironment**

A018 **Exercise stimulates anti-tumoral immunity in metastatic PDAC.** Carolina Alcantara Hirsch. NYU Langone Health, New York, NY, United States.

A019 **Neoplastic co-option of epithelial-immune interactions in pancreatic cancer.** Direna Alonso-Curbelo. IRB Barcelona, Barcelona, Spain.

A020 **Molecular basis of immune suppressive microenvironment specified by cancer-associated fibroblasts in pancreatic cancer.** Kazunori Aoki. National Cancer Center Research Institute Japan, Tokyo, Japan.

A021 **Adjuvant iC9.B7-H3 CAR T Cell-Based Immunotherapy Effectively Eradicate Local and Distant Metastases in Pancreatic Ductal Adenocarcinoma.** Shahrzad Arya. Massachusetts General Hospital, Boston, MA, United States.
A022 Novel nanoparticle delivery of toll like receptor agonists alters the tumor immune landscape and improves response to standard of care therapy in preclinical PDAC models. Nathan Beals. NYU Grossman School of Medicine, New York, NY, United States.

A023 Cytokine loss leads to decreased tumor differentiation and a more aggressive phenotype. Whitney Bell. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

A024 B cells facilitate lymph node colonization in pancreatic ductal adenocarcinoma. Alice Bertocchi. Dana Farber Cancer Institute, Boston, United States.

A025 Autotaxin-lysolipid signaling suppresses a CCL11- eosinophil axis to promote pancreatic cancer progression. Sohinee Bhattacharyya. MSKCC, Union City, NJ, United States.

A026 Senescence driven by pharmacological RAS inhibition potentiates efficacy of combination therapies in pancreatic cancer. Caroline Broderick. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A027 Aberrant glycosylation in mPDAC cells is associated with increased recruitment of immunosuppressive cells. Shawna Brookens. University of Pennsylvania, Philadelphia, PA, United States.

A028 Multiomic modelling of pancreatic IPMN stroma reveals distinct tertiary lymphoid structure distribution: mapping the transcriptomic landscape via regional bulk, single-cell and subcellular approaches. Andrew Cameron. School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

A029 Re-purposing non-oncology agent Itraconazole to target the dynamic cellular ecosystem of pancreatic cancer. Diego Chacon-Fajardo. Garvan Institute of Medical Research, Sydney, Australia.

A030 Fusion between macrophages and cancer cells up-regulates signal regulatory protein pathway and contributes to malignant progression of pancreatic cancer after radiation. Hui Ju Chang. National Health Research Institutes, Taipei, Taiwan (Greater China).

A031 Biotherapeutic strategies targeting the CXCR2 axis for depletion of myeloid-derived suppressor cells in pancreatic ductal adenocarcinoma. Benjamin Christopher. Medical University of South Carolina, Charleston, SC, United States.

A032 mTFF2-MSA (mTNX-1700) suppresses tumor growth in an anti-PD-1 treated Pan02 syngeneic pancreatic cancer model by targeting MDSCs in C57BL/6 mice. Bruce Daugherty. Tonix Pharmaceuticals, Inc., Chatham, NJ, United States.

A034 Thermoregulation alters adipose influence of pancreatic cancer growth. Austin Eades. University of Kansas Medical Center, Kansas City, KS, United States.

A035 Stromal composition, fibroblast heterogeneity and spatial organization in pancreatic adenocarcinoma. Dalia Elganainy. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

A036 Quantitative Molecular Imaging of Pancreatic Tumor Fibrosis for Evaluation of Response to Neoadjuvant Therapy; Pre-Clinical and First-in-Human Application of Collagen PET/MRI. Shadi Esfahani. Department of Radiology, Massachusetts General Hospital, Boston, MA, United States.

A037 Unraveling the importance of pancreatic cancer extracellular signaling to endothelial cells within the tumor microenvironment. Jennifer Finan. Oregon Health and Science University, Portland, OR, United States.

A038 Non-canonical MHC class I-associated antigens in pancreatic cancer. William Freed-Pastor. Dana-Farber Cancer Institute, Boston, MA, United States.

A039 Silencing MICAL2 Expression in Pancreatic Cancer Cells Reduces IL-1A Expression and Inhibits Tumor Growth Through a CD8+ T Cell Dependent Mechanism. Bharti Garg. Moores cancer Centre UC SAN diego, SAN diego, CA, United States.

A040 Assessing the ability of Fc3TSR to remodel the tumor microenvironment and enhance efficacy of immunotherapies and chemotherapy in a murine model of pancreatic ductal adenocarcinoma. Bianca Garlisi. Department of Biomedical Sciences, University of Guelph, Guelph, ON, Canada.

A041 Characterizing antigen presentation associated immune escape mechanisms in pancreatic adenocarcinoma using an integrative computational approach. Michael Geuenich. Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada.

A042 Cancer Associated Fibroblasts drive transcriptional changes in tumor cells from classical to basal phenotype and promote Epithelial-to-Mesenchymal Transition in Human Pancreatic Ductal Adenocarcinoma. Samantha Guinn. Johns Hopkins University School of Medicine, Baltimore, MD, United States.

A043 The tumor-intrinsic RNA binding protein HuR is essential for anti-tumor immunity in PDAC. Yifei Guo. Oregon Health and Science University, Portland, OR, United States.

A044 Tumor-infiltrating lymphocyte density correlates with survival in pancreatic adenosquamous carcinoma. Saurav Haldar. Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States.
A045 **Persistence of the splanchnic gene signature along the mesenchymal cell trajectory during pancreatic cancer progression.** Lu Han. Medical University of South Carolina, Charleston, SC, United States.

A046 **Hypoxic regulation of macrophage migration and function in pancreatic cancer.** Sean Hannifin. University of Michigan, Ann Arbor, MI, United States.

A047 **ARID1A mutations drive metastasis of pancreatic neuroendocrine tumors and pancreatic adenocarcinomas by activation of NTN1/UNC5B signaling.** Chris Harris. University of Rochester, Rochester, NY, United States.

A048 **Enhancing the immune response in locally advanced pancreatic cancer (LAPC) with intratumoral endoscopic ultrasound-guided fine needle injection of large surface area microparticle paclitaxel (LSAM-PTX).** Andrew Hendifar. Cedars-Sinai Medical Center, Los Angeles, CA, United States.

A049 **nSMase2-generated ceramide promotes PDA aggression through exosome reprogramming of the stroma.** Audrey Hendley. UCSF, San Francisco, CA, United States.


A051 **PSGL-1-deficiency promotes pancreatic ductal adenocarcinoma tumor control and synergy with immune checkpoint blockade.** Jennifer Hope. Drexel University, Philadelphia, PA, United States.

A052 **Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to immune checkpoint blockade therapy.** Tadashi Iida. Nagoya University, Nagoya, Japan.

A053 **The effects of chemotherapy on B cells and T cells in blood and tumor tissue in patients with pancreatic cancer – from diagnosis to terminal disease.** Hedda Jacobsen. Faculty of medicine, Lund, Sweden.

**Metabolic Perturbations**

A054 **PP2A activation alters macropinosome processing in pancreatic cancer cells leading to metabolic stress and cancer cell death.** Brittany Allen-Petersen. Purdue University, West Lafayette, IN, United States.

A055 **Context-dependent role of acid sphingomyelinase in pancreatic ductal adenocarcinoma.** Ahmed Alnatsha. University Hospital LMU Munich, Munich, Germany.

A056 **Targeting the mevalonate biosynthesis pathway in gemcitabine resistant pancreatic cancer.** Alica Beutel. Molecular Biology and Biochemistry, Irvine, CA, United States.
A057 Decreased Plasma Linoleic Acid and Increased Oleic Acid Associated with Obesity in Pancreatic Cancer. Kaylin Chasser. Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, United States.

A058 Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. Ziheng Chen. UT MD Anderson Cancer Center, Houston, TX, United States.

A059 Targeting Pancreatic Cancer Metabolic Dependencies through Glutamine Antagonism. Joel Encarnacion-Rosado. NYU School of Medicine, New York, NY, United States.

A060 Metabolic patterns in pancreatic cancer cachexia. Deepti Mathur. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Model Systems & Bioengineering

A061 A novel genetically engineered mouse model of Myc-driven pancreatic cancer recapitulates phenotypic heterogeneity, metastasis, and therapy resistance seen in clinical populations. Isabel English. Oregon Health & Science University, Portland, OR, United States.

A062 Chromatin dynamics reveals a differential capacity of Kras mutants to drive epigenetic reprogramming and lineage reversion in PDAC initiation. David Falvo. Weill Cornell Medicine, New York, NY, United States.

A063 Tertiary lymphoid organogenesis and lymphocyte activation in human organ chips. Girija Goyal. Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, United States.

A064 The initiation and progression of pancreatic ductal adenocarcinoma through a p53 lens. Kathryn Hanson. Stanford University, Stanford, CA, United States.

A065 Lineage tracing oncogenic isoforms of HER2 in a mouse model of pancreatic cancer. Elishama Kanu. Duke University Medical Center, Durham, NC, United States.

Other


A067 A single sample classifier of Bailey’s molecular subtype of PDAC. Taisuke Baba. Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

A068 Proteomic analysis of keratin 17 positive cells from laser-capture microdissected pancreatic ductal adenocarcinoma. Ji Dong Bai. Stony Brook University, Stony Brook, NY, United States.
A069 **Study of MUC16/ERBB axis in pancreatic cancer.** Amina Baniya. University of Nebraska Medical Center, Omaha, NE, United States.

A070 **Genomic profiling of pancreatic cancer by KRAS status.** Gargi Basu. Exact Sciences, Phoenix, AZ, United States.


A072 **Keratin 17-signature for stratification of chemotherapy in pancreatic adenocarcinoma.** Sumedha Chowdhury. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06510, USA, New Haven, CT, United States.

A073 **A link between the mitochondrial enzyme glutamic-oxaloacetic transaminase 2 (GOT2) and epigenetic dysregulation in pancreatic cancer.** Luis Francisco Diaz. Oregon Health & Science University, Portland, OR, United States.

A074 **Namodenoson Inhibits the Growth of Pancreatic Carcinoma via De-regulation of the Wnt/β-catenin Signaling Pathway.** Pnina Fishman. Can-Fite BioPharma Ltd., Petah Tikva, Israel.

A075 **Spatial genomic expression profiling reveals differential marker expression patterns in mucinous cystic carcinoma of the pancreas with ductal involvement.** Arshia Ghodrati. University of Illinois College of Medicine, Peoria, IL, United States.

A076 **Spatial genomic expression profiling reveals metastatic gene markers in mucinous cystic carcinoma of the pancreas and regional lymph nodes.** Chirag Gopinath. University of Illinois College of Medicine, Peoria, IL, United States.

A077 **The EZH2 epigenetic factor orchestrates oncogenic properties in ATM-deficient pancreatic cancer.** Johann Gout. Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany.

**RAS, Oncogene addiction, & Other Targeted Therapies**

A078 **Response and resistance to KRAS inhibition in PDAC mouse models.** Laleh Abbassi. Dana Farber Cancer Institute, Boston, United States.

A079 **A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2-deficient pancreatic cancer.** Suyakarn Archasappawat. University of California, Davis, Davis, CA, United States.
A080 **Target genes in pancreatic cancer cells of the pan-quadruplex clinical candidate compound QN-302 revealed by comparative transcriptome profiling.** Tariq Arshad. Qualigen therapeutics Inc, Carlsbad, CA, United States.


A082 **Mechanistic insights in a novel two-drug therapeutic intervention for p53 mutant pancreatic cancer.** Andrei Bakin. Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

A083 **Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma.** Rachael Baliira. University of Michigan, Ann Arbor, MI, United States.

A084 **Photo Activation of Multi-Inhibitor Nanoliposomes: Impacting Cancer Therapy by overcoming challenges in drug delivery and treatment specificity.** Shazia Bano. Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

A085 **First-in-class humanized antibody targeting alternatively spliced tissue factor augments anti-metastatic efficacy of chemotherapy in a preclinical model of pancreatic ductal adenocarcinoma.** Vladimir Bogdanov. College of Medicine, University of Cincinnati, Cincinnati, OH, United States.

A086 **TFEB protects pancreatic cancer cells against nucleolar stress.** Marie-Josee Boucher. University of Sherbrooke, Sherbrooke, QC, Canada.

A087 **Loss of KDM5A supports KRAS-driven pancreatic cancer.** Jasper Chen. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A088 **Radiopharmaceutical therapy for pancreatic cancer: Engineered anti-prostate stem cell antigen (PSCA) antibody demonstrates targeted imaging and antitumor effects in a syngeneic mouse model of pancreatic ductal adenocarcinoma (PDAC).** Bao Ying Chen. City of Hope, duarte, CA, United States.


A090 **Eradication of PANC1 human PDAC cells in xenografts while targeting the protein NuMA.** Malka Cohen-Armon. Tel-Aviv University, Tel-Aviv, Israel.

A091 **The RAF/MEK clamp avutometinib as the backbone of therapy for pancreatic cancer: Novel combinations with standard of care chemotherapy, FAK inhibitors, KRAS G12D inhibitors and/or autophagy inhibitors.** Silvia Coma. Verastem Oncology, Needham, MA, United States.
A092 **Exploiting the neural-like properties of a new pancreatic cancer morpho-biotype for the development of a combinatorial treatment targeting tumor heterogeneity.** Giuseppe Diaferia. European Institute of Oncology, Milan, Italy.

A093 **Deciphering Acquired Resistance to KRASG12D Inhibition in a Mouse Model of Pancreatic Ductal Adenocarcinoma.** Julien Dilly. Dana-Farber Cancer Institute, Boston, MA, United States.

A094 **LIN28B/HMGA2 axis accelerates PDA by promoting oncogenic protein synthesis.** Stephanie Dobersch. Fred Hutchinson Cancer Center, Seattle, WA, United States.

A095 **ZNF274 suppresses the mesenchymal state, thereby causing intrinsic resistance to CDK7 inhibition.** Jessica Gianopulos. Fred Hutchinson Cancer Center, Seattle, WA, United States.

A096 **PIKfyve as a potential therapeutic target in pancreatic cancer.** Shea Grenier. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.


A099 **Utilising interactomics to uncover oncogenic KRAS signalling networks in the context of the tumour microenvironment.** Nasir Haider. Cancer Research UK Manchester Institute, Manchester, United Kingdom.

A100 **KRAS inhibition targets and depends on pro-oncogenic HuR in PDAC cells.** Hen Halamish. Oregon Health & Science University, Portland, OR, United States.

A101 **Codon-specific KRAS mutations predict survival in advanced pancreatic cancer.** Marc Hilmi. Institut Curie, Saint-Cloud, France.

A102 **Secreted frizzled related-protein 2 is prognostic for survival in pancreatic cancer.** Lillian Hsu. Medical University of South Carolina, Charleston, SC, United States.

A103 **Developing small molecules to disrupt IL-17RB and MLK4 interaction for pancreatic cancer treatment.** Chun-Mei Hu. Academia Sinica, Taipei, Taiwan (Greater China).

A104 **Targeting RABL3 to disrupt KRAS trafficking and activity in pancreatic cancer.** Woo-Jeong Jeong. Brigham and Women’s Hospital, Boston, United States.

A105 **Wild-type IDH1 inhibition enhances chemotherapy response in pancreatic cancer.** Mehrdad Zarei. Case Western Reserve University, Cleveland, OH, United States.

**Systems Biology, Big Data, and Metastasis**

A107 MAPK signaling is a conserved mechanism explaining phenotypic heterogeneity across diverse drivers of epithelial-mesenchymal transition in pancreas cancer. Michelle Barbeau. The University of Virginia, Charlottesville, VA, United States.


A109 Single-cell epigenomic analysis reveals an important role of the receptor kinase Ror2 in the erosion of cellular identity during pancreatic carcinogenesis. Simone Benitz. Henry Ford Health System, Detroit, MI, United States.

A110 Clec4f is expressed in a subset of primary PDAC cells and confers invasive behavior. Bailey Bye. University of Kansas Medical Center, Kansas City, KS, United States.

A111 Single-cell analysis identifies landscape alterations of cell populations between primary pancreatic tumor and liver metastasis. Yang Chen. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A112 Liquid biopsy shows distinctive proteome of long-term recurrence free survivors after PDAC resection. Teresa Colbatzky. Heidelberg University Hospital, Heidelberg, Germany.

A113 Coexisting morpho-biotypes unveil the regulatory bases of phenotypic plasticity in pancreatic ductal adenocarcinoma. Pierluigi Di Chiaro. European Institute of Oncology IRCCS, Milano, Italy.


A116 A machine learning-derived transcriptomic-based biomarker identifies low grade pancreatic ductal adenocarcinoma tumors and may help in treatment decision making. Daniel Fu. New Jersey Medical School, Rutgers University, Newark, NJ, United States.


A118 Chromatin accessibility profiling of human pancreatic tumors reveals epigenetic features of malignancy and rapid recurrence. Kevin MacPherson. Oregon Health & Science University, Portland, OR, United States.
Poster Session B (To be presented on September 28 from 4:40-6:30 p.m. ET)

Clinical Updates (Including Trials in Progress)

B001 Impedance Based Biomarker for “smart ROSE” Pancreatic Cancer Detection: Initial Results from an Ongoing Clinical Trial with nsCanary. Federica Dibennardo. NovaScan Inc., Chicago, IL, United States.

B002 Phase I Study of Endoscopic Ultrasound (EUS)-guided NBTXR3 delivery activated by Radiotherapy (RT) for Locally Advanced or Borderline Resectable Pancreatic Cancer (LAPC or BRPC). Gabriela Fuentes. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B003 Advancing biomarker discovery using a novel window of opportunity (WOO) trial for pancreatic ductal adenocarcinoma: trial updates. Shaun Goodyear. Oregon Health and Science University, Portland, OR, United States.

B004 EUS guided local administration of large surface area microparticle paclitaxel with neoadjuvant chemotherapy in locally advanced pancreatic cancer: A single center experience. Harishankar Gopakumar. University of Illinois College of Medicine, Peoria, IL, United States.

B005 A phase 1 expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in metastatic pancreatic adenocarcinoma. Brandon Huffman. Dana-Farber Cancer Institute, Boston, MA, United States.

Epidemiology and Early Detection


B009 Identifying of a novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood. Eun-Young Koh. Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of.

B010 A comprehensive study of clinical features, prognostic factors and survival in patients with pancreatic solid pseudopapillary neoplasm under the 2019 WHO classification. WenHao Luo. Peking Union Medical College Hospital, Beijing, China (Mainland).
B011 **A Comprehensive Study of Cancer-Specific Survival in Patients with Pancreatic Signet Ring Cell Carcinoma: Analysis of 583 Cases from 2000 to 2019.** Wenhao Luo. Peking Union Medical College Hospital, Beijing, China (Mainland).

B012 **TP53 missense mutations and Keratin 17 are negative prognostic biomarkers in pancreatic ductal adenocarcinoma.** Carlos Mauricio Mejia Arbelaez. Yale School of Medicine-Department of Pathology, New Haven, CT, United States.

**Immunology and the Microenvironment**

B013 **Effect of aging on pancreatic cancer progression.** Deepika Bhullar. Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA, United States.

B014 **Immuno-modulation of the tumor microenvironment of pancreatic adenocarcinoma following isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT).** Christelle Bouchart. Institut Jules Bordet - HUB, Brussels, Belgium.

B015 **Toxin-producing bacterial therapy limits tumor growth in autochthonous mouse models of pancreatic ductal adenocarcinoma.** Amanda Decker-Farrell. Columbia University Irving Medical Center, New York, NY, United States.

B016 **Eosinophils alter metastatic spread in pancreatic cancer.** Megan Hoffman. Dana-Farber Cancer Institute, Boston, MA, United States.

B017 **NINJA PDAC: A robust murine pancreatic cancer organoid transplant model with inducible neoantigens for studying tumor microenvironment interactions with anti-tumor T-cell immunity.** Jeremy Jacox. Yale University, New Haven, CT, United States.

B018 **Quantification of immune cell subtypes identified in the pancreatic tumor microenvironment using multiple immunostaining techniques and analysis of correlation between immune cells and patient survival rates.** Ji Hye Jeong. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of.

B019 **Tumor-derived PTHrP molds an immunosuppressive microenvironment.** Calvin Johnson. UMass Chan Medical School, Worcester, MA, United States.

B020 **Charting the cellular heterogeneity of primary and metastatic PDAC microenvironment.** Claus Jorgensen. Cancer Research UK Manchester Institute, Manchester, United Kingdom.

B021 **Clonal heterogeneity in human pancreatic adenocarcinoma and its contribution to therapeutic resistance.** Despoina Kalfakakou. New York University Grossman School of Medicine, New York, NY, United States.
B022 A platform to characterize hepatic immunity reveals variation in hepatic infiltration of tumor expanded T cells in “localized” PDAC. Elishama Kanu. Duke University Medical Center, Durham, NC, United States.

B023 Hypoxia supports CAF-mediated epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma. Karl Kowalewski. University of Virginia, Charlottesville, VA, United States.

B024 Hypoxia at 3D organoid establishment selects essential subclone within heterogenous pancreatic cancer. Koichiro Kumano. Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

B025 IL-1 blockade prevents cardiac toxicity and improves immunotherapy efficacy in mouse models of pancreatic cancer. Heena Kumra. Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States.


B027 Neuropeptide Y Silencing Negatively Impacts the Pancreatic Cancer Cells Invasion Capacity. Gokalp Kurtoglu. Acıbadem University School of Medicine, ISTANBUL, Türkiye.

B028 Fibroblast PIN1 regulates growth factor and metabolic crosstalk to impact a subset of pancreatic cancer cells. Ellen Langer. Oregon Health & Science University, Portland, OR, United States.


B031 Targeting epigenetic machinery to revoke stromal pro-tumorigenicity and enhance efficacy in pancreatic cancer therapy. Gaoyang Liang. Salk Institute for Biological Studies, La Jolla, CA, United States.

B032 Spatial proteomics and transcriptomics reveal early immune cell organization in human pancreatic intraepithelial neoplasia. Melissa Lyman. Johns Hopkins University School of Medicine, Baltimore, MD, United States.

B034 **Antigen-presenting cancer-associated fibroblasts are found in immunotherapy-sensitive murine models of pancreatic ductal adenocarcinoma.** Saumya Maru. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States.

B035 **Investigating the roles of GLI transcription factors in the pancreatic cancer microenvironment.** Paola Medina-Cabrera. University of Michigan, Ann Arbor, MI, United States.

B036 **Exploration of the Human Leukocyte Antigen immunopeptidome in pancreatic adenocarcinoma.** William Miklavcic. University of Nebraska Medical Center, Omaha, NE, United States.

B037 **Anti-Fibrotic FAK ‘priming’ to improve contemporary chemotherapy in pancreatic cancer.** Kendelle Murphy. Garvan Institute of Medical Research, Sydney, Australia.

B038 **Influence of pathological pericyte on PDAC tumor microenvironment.** Vikneshwari Natarajan. North Dakota State University, Fargo, ND, United States.

B039 **Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer.** Tenzin Ngodup. University of Michigan, Ann Arbor, MI, United States.

B040 **Neural control of cancer-associated fibroblasts in PDAC.** Jeremy Nigri. CSHL, Cold Spring Harbor, NY, United States.

B041 **Keratin 17 excludes CD8-positive T cells and recruits CD163-positive macrophages in pancreatic ductal adenocarcinoma.** Lyanne Oblein. Stony Brook University, Stony Brook, NY, United States.

B042 **Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC).** Catherine O’Connor. Memorial Sloan Kettering Cancer Center, New York City, NY, United States.

B043 **Dual epigenetic therapy combined with anti-PD1 rescues HMA-induced suppressive myeloid phenotype and reduces tumor growth in a PDAC model.** Arturo Orlacchio. NYU Grossman School of Medicine, New York, NY, United States.

B044 **Targeting integrin alpha V beta 3 remodels the tumor microenvironment in pancreatic cancer.** Mayrel Palestino Dominguez. National Institutes of Health, National Cancer Institute, Center for Cancer Research, Laboratory of Molecular Biology., Bethesda, MD, United States.


B047 **53BP1 loss mediated PARP inhibitor resistance in BRCA1-deficient pancreatic cancer is overcome with immune checkpoint blockade.** Jeffrey Patterson-Fortin. Dana-Farber Cancer Institute, Boston, MA, United States.

B049 Pancreatic beta cell stress pathways drive pancreatic ductal adenocarcinoma development in obesity. Cathy Garcia. Yale University, New Haven, CT, United States.

B050 Determining the Anti-Cancer Properties of a Ketogenic Diet Against Pancreatic Cancer. Omid Hajihassani. CWRU, CLEVELAND, OH, United States.


B053 Physical Activity Regulates Targetable Transcriptomic Changes in the Adipose Tissue of Obese PDAC Mice. Hsiang-Yin Hsueh. The Ohio State University, Columbus, OH, United States.


Model Systems & Bioengineering

B056 Selective epithelial activation of KRAS G12D mutation drives ductal pancreatic neoplasia in pigs. Carlos Jara. University of Nebraska Medical Center, Omaha, NE, United States.

B057 An organoids-on-a-Chip model to recapitulate and dissect the tumor microenvironment of PDAC. Lunan Liu. Tandon School of Engineering, New York University, Brooklyn, NY, United States.

B058 Mutant GNAS drives glycolytic dependency in intraductal papillary mucinous neoplasms of the pancreas. Yuki Makino. Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B060 Enhancing models of pancreatic cancer: Integrating patient-derived models with tissue engineering to investigate clinical responses to therapy. Alexander Smith. Brenden-Colson Center for Pancreatic Care, Oregon Health and Sciences University, Portland, OR, United States.

B061 Development of a pancreatic ductal adenocarcinoma 3D tumor model for high-throughput drug Screening. Xiaoyu Song. University of Tsukuba, Tsukuba, Japan.

Other

B062 CRO67 has therapeutic potential against pancreatic tumor cells and cancer associated fibroblasts. Keilah Garcia Netto. UNSW, Sydney, NSW, Australia.

B063 The microbiota regulates PDAC progression by modulating acinar cell transcription through toll-like receptors. Diane Hernandez. University of Utah, Salt Lake City, UT, United States.


B065 Biomarker approach to define tumor subtype in pancreatic ductal adenocarcinoma. Carson Ho. Stony Brook University, Stony Brook, NY, United States.


B068 Retrospective pilot study of a natural language processing model approach for earlier identification of patients with pancreas cancer. Kristen John. Zucker School of Medicine, New Hyde Park, NY, United States.

B069 Double-stranded RNA derived from tandem repeat sequences induces mesenchymal transition in pancreatic cancer cells by regulating alternative splicing. Takahiro Kishikawa. The University of Tokyo, Tokyo, Japan.

B070 Histone deacetylation inhibition promotes bi-directional subtype switch in pancreatic cancer. Lukas Klein. University Medical Center Göttingen, Göttingen, Germany.

B072 **SMAD4 loss allows progression from benign to malignant disease in intraductal papillary mucinous neoplasms.** Anna Means. Vanderbilt University Medical Center, Nashville, TN, United States.

B073 **Understanding treatment response in pancreatic cancer: NetraAI provides genetic differentiation in FOLFIRINOX and Gemcitabine response.** Bessi Qorri. NetraMark Corp, Toronto, ON, Canada.

B074 **Clinical inference of location and trajectory of pancreatic cancer from radiology reports using zero-shot LLM.** Travis Zack. University of California, San Francisco, San Francisco, CA, United States.

**RAS, Oncogene addiction, & Other Targeted Therapies**

B075 **Multiple types of actin filaments define the mechanobiology potential of pancreatic cancer tumours and one is required for cell survival.** Peter Gunning. UNSW, Sydney, NSW, Australia.

B076 **Development of Novel Gemcitabine-Modified miRNA Mimics For Pancreatic Ductal Adenocarcinoma.** Jingfang Ju. Stony Brook University, Stony Brook, NY, United States.

B077 **KRASG12D inhibitor MRTX1133 synergizes with the next generation nuclear transport protein inhibitor eltanexor resulting in enhanced antitumor activity against pancreatic ductal adenocarcinoma.** Husain Khan. Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, United States.

B078 **A complex of NF1 and SPRED2 non-canonically behave as tumor promoters in pancreatic cancer.** Sun Kim. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.

B079 **Identification of synergistic drug combinations including MEK inhibitor and agents modulating the tumor microenvironment in an electroporation-induced pancreatic cancer model.** Aline Konrad. German Cancer Research Center, Heidelberg, Germany.

B080 **Mutant-selective KRASG12D (ON) inhibitor suppresses proliferation in vitro and tumor growth in vivo of KrasG12D GEMM-derived PDAC organoids.** Mark Labrecque. Revolution Medicines, Redwood City, CA, United States.

B081 **SOAT1 as a targetable KRAS dependency in PDAC.** Wenjun Lan. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.

B082 **Extinction of oncogenic Kras in genetic mouse models eradicates pancreatic cancer by inducing Fas-dependent apoptosis by CD8+ T cells.** Valerie LeBleu. Baylor College of Medicine, Houston, TX, United States.


B085 K17-induced pyrimidine biosynthesis drives chemoresistance in PDAC. Yinghuan Lyu. Stony Brook University, Stony Brook, NY, United States.

B086 KRASG12D specific inhibitor reprograms tumor microenvironment to prevent and reverse early neoplasms and combined with immunotherapy regresses advanced PDAC via FAS and CD8+T cells. Krishnan Mahadevan. MD Anderson Cancer center, Houston, TX, United States.


B088 The Macropinosome: Uncovering the Molecular Anatomy of an Oncogene-driven Organelle. Ambroise Manceau. Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA, United States.

B089 Oncogenic signaling and responses to treatment in RAS mutant cancers are mutation-specific. Michelangelo Marasco. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B090 Targeting the unfolded protein response enhances sensitivity to chemotherapy. Mckenzie Martin. University of Western Ontario, London, ON, Canada.

B091 The mammalian 8-oxodGTPase, MTH1, as a novel targetable vulnerability in pancreatic ductal adenocarcinoma. Beatriz Mateo-Victoriano. University of Miami, Miami, FL, United States.

B092 CDK8 and CXCL2 remodel the tumor microenvironment to contribute to KRASG12D small molecule inhibition resistance in pancreatic ductal adenocarcinoma. Kathleen McAndrews. MD Anderson Cancer Center, Houston, TX, United States.

B093 Alcoholic Chronic Inflammation Driven CREB Mediates Acinar-to-Ductal Reprogramming and Promote Neoplastic Progression. Siddharth Mehra. University of Miami, Miami, FL, United States.

B094 The role of paraspeckles and splicing regulation in driving basal-like pancreatic cancer. Stephano Mello. University of Rochester, Rochester, NY, United States.

B095 Leukemia inhibitory factor fosters tumor growth in KRAS-driven pancreatic ductal adenocarcinoma. Lisa Miller-Phillips. Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA, United States.

B096 Acquired resistance to KRAS inhibition modulates the pancreatic cancer tumor microenvironment. Kevin Montecillo Gulay. University of California, San Diego, La Jolla, CA, United States.
B097 Tomatidine inhibits ATF4 activity and induces ferroptosis to limit pancreatic cancer progression. Debasmita Mukherjee. The Ohio State University, Columbus, OH, United States.

B098 Oncogenic KRAS relies on β1 integrin expression to drive pancreatic neoplasia and PDAC development. John Muschler. Oregon Health and Science University, Portland, OR, United States.

B099 Aberrant glycosylation in pancreatic ductal adenocarcinoma 3D organoids is mediated by KRAS mutations. Hiromitsu Nakahashi. University of Tsukuba, Tsukuba city, Japan.

B100 Netrin-1/Neogenin-1 interaction modulates pancreatic innervation to promote tumorigenesis and accelerates cancer progression. Yosuke Ochiai. Columbia University Medical Center, New York, NY, United States.


B102 Development of covalent inhibitors targeting Ras Q61 hotspot mutants. Julius Pampel. University of California San Francisco and Howard Hughes Medical Institute, San Francisco, CA, United States.

B103 Development and characterisation of KRASmulti inhibitors for the treatment of KRAS mutant Pancreatic Ductal Adenocarcinoma. Mark Pearson. Boehringer Ingelheim RCV GmbH Co KG, Oncology Research, Dr. Boehringer-Gasse 5-11, 1121, Vienna, Austria.

B104 Epigenetic small molecule library screen to discover compounds that inhibit and reverse pancreatic acinar to ductal metaplasia. Corey Perkins. University of Florida, Gainesville, FL, United States.

Systems Biology, Big Data, and Metastasis

B105 Delta CT-Radiomics Derived Response Prediction in Advanced Pancreatic Ductal Adenocarcinoma. Felix Harder. Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Avenue, M5G 1X5, Toronto, ON, Canada, Toronto, Canada.

B106 Spatially-constrained optimal transport interaction analysis reveals therapy-associated remodeling in the pancreatic cancer microenvironment. William Hwang. Massachusetts General Hospital, Boston, MA, United States.


B109 Reinforcing risk prediction for intraductal papillary mucinous neoplasms of the pancreas with AI-optimized nucleotide-to-amino acid analyses. Aleksandra Karolak. Moffitt Cancer Center, Tampa, FL, United States.


B111 Developing prognostic signatures (ep-Sigs) through epigenetic predictive markers in pancreatic ductal adenocarcinoma (PDA) – a pilot study based on The Cancer Genome Atlas (TCGA) data. Ashish Manne. The Ohio State University, Columbus, OH, United States.

B112 Single-cell profiling of neoplastic cell populations in a KRAS-initiated zebrafish pancreatic cancer model. Somer Matar. Dartmouth College, Hanover, NH, United States.


B115 Single-cell transcriptomic analysis reveals both shared and separate functions for GATA6 and KRT17 in pancreatic cancer. Brian Nelson. Stony Brook University, Stony Brook, NY, United States.


B117 Clonal evolutionary study reveals diverse patterns of progression of IPMN malignant transformation. Antonio Pea. University of Verona, Verona, Italy.
Clinical Updates (Including Trials in Progress)

C001 A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma. Kelsey Klute. University of Nebraska Medical Center, Omaha, NE, United States.

C002 Interleukin-1 receptor accessory protein (IL1RAP) overexpression is associated with worse prognosis in PDAC and is targetable by nadunolimab. David Liberg. Cantargia AB, Lund, Sweden.

C003 RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma. Kian Lim. Department of Medicine, Washington University in St. Louis, St. Louis, MO, United States.


C005 A Phase 1b/2 trial of pepinemab and avelumab as second line immunotherapy for patients with chemotherapy refractory metastatic pancreatic adenocarcinoma. Luis Ruffolo. University of Rochester Medical Center, Rochester, NY, United States.

Epidemiology and Early Detection

C006 Combining the methylation and gene expression contiguous signals leads to better pancreatic cancer patient stratification and early detection. Kristi Kruusmaa. UniversalDx d.o.o., Ljubljana, Slovenia.


C008 MUC16 expression in pancreatic ductal adenocarcinoma patient samples after neoadjuvant chemotherapy. Kathryn Muilenburg. University of Nebraska Medical Center, Omaha, NE, United States.

C010 Identification of a panel of miRNAs as biomarkers for early-stage detection of pancreatic cancer: a randomized cohort study. Gary Xiao. Dalian University Of Technology, Dalian, China (Mainland).

C011 Detection of circulating tumor cells for the early detection of pancreatic cancer. Dannel Yeo. Centenary Institute, Sydney, Australia.

Immunology and the Microenvironment
C012 **TIGIT expression correlates to worse overall survival in primary and metastatic pancreatic ductal adenocarcinoma.** Madison George. Henry Ford Health, Detroit, MI, United States.

C013 **Analysis of tumor immune microenvironment and clinical outcomes in undifferentiated pancreatic carcinomas with and without osteoclast-like giant cells.** Jamie Mills. University of Michigan, Ann Arbor, MI, United States.

C014 **CXCR4 inhibition enhances anti-tumor immune response in an ex vivo autologous patient-derived organoids and PBMC model system of pancreatic ductal adenocarcinoma.** Ilenia Pellicciotta. COLUMBIA UNIVERSITY, NEW YORK, NY, United States.


C016 **Pre-existing T cell inflammation is a determinant of response to mesothelin chimeric antigen receptor T cell therapy in Pancreatic Ductal Adenocarcinoma.** Jacqueline Plesset. University of Pennsylvania, Philadelphia, PA, United States.

C017 **The anti-fungal itraconazole improves immunotherapy efficacy in pancreatic ductal adenocarcinoma by reversing the immune-suppressive tumour microenvironment.** Sean Porazinski. Garvan Institute of Medical Research, Sydney, NSW, Australia.

C018 **Spatial profiling of tumor associated cells expressing endoplasmic reticulum stress proteins predicts poor outcomes in pancreatic cancer patients.** Georgia Porter. Children’s Cancer Institute, Sydney, NSW, Australia.

C019 **The circadian master regulator BMAL1 blocks immune cell recognition of pancreatic ductal adenocarcinomas by reducing proteasome activity and MHC1 cell surface localization.** Orjola Prela. University of Rochester, Rochester, NY, United States.

C020 **Unconvering the hidden immunosuppressive landscape in pancreatic ductal adenocarcinoma.** Guhan Qian. University of Minnesota, Minneapolis, United States.

C021 **Granulocytic MDSC-derived NLRP3 inflammasome activation is a novel regulator of inflammatory CAF skewness in pancreatic cancer.** Karthik Rajkumar. University of Miami, Miami, FL, United States.

C022 **T cell movement through complex obstacles presented by the microenvironment of pancreatic tumor spheroids.** Shambojit Roy. University of Minnesota, Twin Cities, MINNEAPOLIS, MN, United States.

C023 **PTEN/STAT3 pathway in cancer-associated fibroblasts in Pancreatic Cancer.** Samaneh Saberi. Medical University of south Carolina, Charleston, SC, United States.

C025 Fibroblast-specific IL1R1-p38 MAPK signaling sustains stromal inflammation and contributes to therapeutic resistance in pancreatic cancer. Samara Singh. University of Miami, Miller School of Medicine, Miami, FL, United States.


C028 DKK3 in pancreatic cancer – elucidating the roles of a double-edged sword. Dharini Srinivasan. Institute of Molecular Oncology and Stem cell biology, University medical center Ulm, Ulm, Germany.


C030 Serum levels and tumor tissue organization of decorin in pancreatic cancer: links to chemoresistance and disease aggressiveness. Maja Svensson. Lund University, Lund, Sweden.

C031 Differential growth of pancreatic ductal adenocarcinoma cells in Serum Amyloid A (SAA) deficient mouse model through immune modulation. Yuki Takamuku. Beckman Research Institute of City of Hope, Duarte, CA, United States.

C032 The involvement of the splanchnic program at the cellular and molecular levels in pancreatic cancer associated fibroblasts. Tom Walter. College of Charleston, Charleston, SC, United States.


C034 Genome-wide CRISPR screen identifies novel immunotherapeutic targets in pancreatic cancer. Xiaofei Wang. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C035 Enhanced cytokine signaling and ferroptosis defense interplay promotes obesity-associated pancreatic ductal adenocarcinoma. Chengcheng Wang. Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China (Mainland).

C037 **Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer.** Chengcheng Wang. Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China (Mainland).

C038 **Interim pharmacodynamic analyses of mitazalimab in combination with FOLFIRINOX in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) identify CD4 effector T cells as a correlate of treatment outcomes.** Max Wattenberg. University of Pennsylvania, Philadelphia, PA, United States.

C039 **Disruption of ADAM17-dependent cellular crosstalk inhibits tumor progression of pancreatic ductal adenocarcinoma.** Hui-Ju Wen. Henry Ford Pancreatic Cancer Center, Detroit, MI, United States.

C040 **Investigating oncogene-inflammation cooperativity in pancreatic cancer.** Katharina Woess. Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

C041 **Oncostatin-M and Transforming Growth Factor-beta promote loss of PTEN in PDAC Cancer Associated Fibroblasts.** Ivo Woogeng. Medical University of South Carolina (MUSC), Charleston, SC, United States.

C042 **Discovery of a core inflammatory gene network associated with poor prognosis and characterized immune infiltration pattern in pancreatic ductal adenocarcinoma.** Liu Yang. Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, SAR, China; Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Med, HongKong, Hong Kong (Greater China).

C043 **Spatial Proteomic Immune Profiling of Pancreatic Ductal Adenocarcinoma and the Tumor Microenvironment.** Jason Yeung. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

C044 **Macropinocytic stress reprograms cancer-associated fibroblasts and enhances therapeutic responses in pancreatic cancer.** Yijuan Zhang. Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA, United States.


C046 **Enhancing T cell Infiltration and Migration in the Pancreatic Tumor Microenvironment.** Hongrong Zhang. University of Minnesota, Minneapolis, MN, United States.

**Metabolic Perturbations**

C048 Obesity transforms the gut microbiome to invoke a cancer permissive state. Christian Ruiz. Yale University, New Haven, CT, United States.

C049 Loss of RNF43 creates an OXPHOS dependency in early pancreatic neoplasia. Akiko Sagara. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C050 The Unique Metabolic Signatures of Keratin-17 Expressing Pancreatic Ductal Adenocarcinomas. Mahmoud Salem. Stony Brook, brooklyn, NY, United States.

C051 CYP3A5 regulates glucose metabolism through 4EBP1-TXNIP-GLUT1 axis in pancreatic cancer. Ming Shao. St. Jude Children’s Research Hospital, Memphis, TN, United States.

C052 Ketogenic diet enhanced nutrient metabolic pathways but did not inhibit tumor growth in an obesity-associated PDAC mouse model. Ericka Velez-Bonet. The Ohio State University, Columbus, OH, United States.


Model Systems & Bioengineering

C055 Activation of oncogenes within Tff2 expressing cells of the pancreatic ductal glands results in increased lineage stemness preceding tumorigenesis: Insights from an inducible mouse model and derived organoids. Kyle McAndrews. University of Nebraska Medical Center, Omaha, NE, United States.


C057 Delineating tissue-specific oncogene selection with autochthonous CRISPR activation screening. Fredrik Thege. UT MD Anderson Cancer Center, Houston, TX, United States.

C059 Hub gene analysis identifies CAD as a potential mediator for drug resistance in pancreatic cancer.
Foram Vyas. University of Toronto, Toronto, ON, Canada.


Other

C061 Therapeutic profiling, patient response prediction, and tumor evolution in pancreatic cancer organoids. Johann Gout. Institute for Molecular Oncology and Stem Cell Biology, Ulm, Germany.

C062 Lipocalin 2 slows myoblast growth and contributes to pancreatic cancer-associated muscle wasting. Kristyn Gumpper-Fedus. The Ohio State University Wexner Medical Center, Columbus, OH, United States.

C063 Keratin 17 as a predictor of chemotherapy response in pancreatic ductal adenocarcinoma. Lyanne Oblein. Stony Brook University, Stony Brook, NY, United States.

C064 Chronic platinum exposure induces cell-intrinsic type1 interferon/STING pathway activation in homologous recombination-deficient pancreatic cancer to drive sensitivity to checkpoint immunotherapy. Ifeanyichukwu Ogobuiro. University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, United States.

C065 Base Excision Repair Pathway Regulates Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma. Mustafa Raoof. City of Hope Cancer Center, Duarte, CA, United States.

C066 Metaplastic tuft cells transdifferentiate into metaplastic neuroendocrine cells as pancreatic cancer progresses into late stage carcinoma. Daniel Salas-Escabillas. University of Michigan/Henry Ford Pancreatic Cancer Center, Ann Arbor, MI, United States.

C067 Correlation of Keratin17 Expression with Tumor Cell Proliferation and Invasion in PDAC. Shayan Sarkar. Stony Brook University, Stony Brook, NY, United States.

C068 Construction of preclinical study model for optimal anticancer drug selection using PDX model in pancreatic cancer. Ryota Tanaka. Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

C069 Energy decomposition and waterswapping analysis to investigate the SNP associated DPD mediated 5-FU resistance. Himanshu Verma. Punjabi University, Patiala, India.

C071 Radiomics of pre-operative CT scans capture biologic processes within the liver in patients undergoing pancreatectomy. Constantinos Zambririnis. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States.

C072 Andrographolide exhibits anti-cancer activity via restoring DNMT3B-suppressed ZNF382 expression in pancreatic cancer. Kai-Ru Zhuang. Institute of Traditional Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan (Greater China).

RAS, Oncogene Addiction, & Other Targeted Therapies

C073 Down-regulation of ROCK increases the chemo-sensitivity and inhibits the progression of pancreatic cancer cells. Wenhao Luo. Peking Union Medical College Hospital, Beijing, China (Mainland).

C074 Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages. Maria Perry. Memorial Sloan Kettering Cancer Center, Department of Pathology and Laboratory Medicine, New York, NY, United States.

C075 Altered RNA splicing causes pancreatic cancer and exposes a therapeutic vulnerability. Natasha Pinto Medici. Yale University, New Haven, CT, United States.


C078 Inhibiting the autophagy-lysosomal pathway in pancreatic ductal adenocarcinoma using novel small molecules. Yangjingyi Ruan. Weill Cornell Medicine/ Memorial Sloan Kettering Cancer Center, New York, NY, United States.

C079 Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new approach to treat pancreatic cancer. Bruno Sainz. Department of Biochemistry, Autónoma University of Madrid, School of Medicine, Instituto de Investigaciones Biomédicas (Iibm) "Alberto Sols" CSIC-UAM, Chronic Diseases and Cancer, Area 3, Instituto Ramón y Cajal de Investigación Sanitaria (IRyCIS), Madrid, United States.

C080 Decoding the MYC-PDAC nexus: unveiling the impact of PP2A-C subunit methylation on tumor onset and advancement. Vidhi Shah. Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, OR 97201, OR, United States.

C081 The lysine demethylase KDM4C is an oncogenic driver in pancreatic ductal adenocarcinoma. Menna-t-Allah Shaheen. MD Anderson Cancer Center, Houston, TX, United States.
C082 **Decoding the KRAS-Dependent Proteome through the Ribosomal Lens.** Kamini Singh. Albert Einstein College of Medicine, Bronx, NY, United States.

C083 **SMNDC1 alters the splicing of ERK to potentiate its activity in pancreatic cancer.** Md Afjalus Siraj. Yale University, New Haven, CT, United States.

C084 **iExplore: A phase I study of mesenchymal stem cell derived exosomes with KrasG12D siRNA for metastatic pancreas cancer patients harboring the KrasG12D mutation.** Brandon Smaglo. MD Anderson Cancer Center, Houston, TX, United States.

C085 **Conquering Undruggable and Incurable Human Pancreatic Cancer by Attacking its Achilles’ Heel, SIAH Proteolysis – A Major Tumor Vulnerability and the Key Signaling Gatekeeper in the Oncogenic EGFR/K-RAS Pathway.** Amy Tang. Eastern Virginia Medical School, Leroy T. Canoles Jr. Cancer Center, Norfolk, VA, United States.


C087 **Window-of-opportunity trial of metastatic pancreatic cancer reveals mechanisms of response to targeting RAS signaling.** Motoyuki Tsuda. Oregon health & Science University, portland, OR, United States.

C088 **Preclinical synergistic combination therapy of lurbinectedin with irinotecan and 5-fluorouracil in pancreatic cancer.** Tej Tummala. Legorreta Cancer Center at Brown University, Providence, RI, United States.

C089 **A novel role of p53 in pancreatic acinar cell identity.** Jennifer Twardowski. University of Rochester Medical Center, Rochester, NY, United States.

C090 **Elucidation of misp53-driven subtype specification and functions in pancreatic cancer.** Laura Urbach. Department of Gastroenterology, Gastrointestinal Oncology & Endocrinology, University Medical Center Göttingen, Göttingen, Germany.

C091 **Harnessing proteostatic vulnerabilities in pancreatic cancer.** Sandra Vogt. NYU Grossman School of Medicine, New York, NY, United States.

C092 **T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with Minimal Residual Disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile lymph node targeted mutant KRAS vaccine.** Zev Wainberg. University of California, Los Angeles, Los Angeles, CA, United States.

C094 Tff2 defines pancreatic TA progenitors that are protective against Kras-driven carcinogenesis. Feijing Wu. Columbia University, New York, NY, United States.


C096 Targeting Syndecan1 to overcome acquired resistant to KRAS inhibitor in gastrointestinal cancer. Wantong Yao. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C097 KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-driven tumors to Sotorasib treatment. Haoqiang Ying. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C098 Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Abdelrahman Yousef. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

C099 Mutant-selective, covalent inhibitors of K-Ras(G12D). Qinheng Zheng. UCSF, San Francisco, CA, United States.


Systems Biology, Big Data, and Metastasis


C104 Dual primary pancreas cancers – Related or independent lesions?. Joshua Schoenfeld. MSKCC, NY, NY, United States.

C106 **IMPACT restrains immuno-metabolic GCN1 signaling to govern pancreatic cancer metastasis.**
Surajit Sinha. National Cancer Institute, NIH, Bethesda, MD, United States.

C107 **Use of spatial transcriptomics to identify molecular features associated with African American heritage in pancreatic cancer.** Nina Steele. Henry Ford Health+Michigan State University Health Sciences, Detroit, MI, United States.

C108 **Cancer cells co-evolve with retrotransposons to mitigate viral mimicry in pancreatic cancer.** Siyu Sun. Memorial Sloan Kettering Cancer Center, NEW YORK, NY, United States.

C109 **Nanostring-based subtyping of pancreatic ductal adenocarcinoma is strongly influenced by the stromal compartment.** James Topham. Pancreas Center BC, Vancouver, Canada.

C110 **Development of a new individualized prognostic and therapeutic AI pipeline for pancreatic cancer.** Ryan Carr. Brown University, Providence, RI, United States.

C111 **Whole genome bisulfite sequencing of human and mouse organoid models of PDAC progression identifies stage- and subtype-specific DNA methylation signatures.** Sarah Wang. University of California, Davis, CA, United States.

C112 **Cell-in-cell mediated entosis reveals a progressive mechanism in pancreatic cancer.** Chengcheng Wang. Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China (Mainland).


C114 **Engrailed-1 promotes pancreatic cancer metastasis.** Jihao Xu. University of California Davis, Davis, CA, United States.

C115 **Genomic evolution of pancreatic cancer at single-cell resolution.** Haochen Zhang. Memorial Sloan Kettering Cancer Center, New York, NY, United States.